FC
NBIX icon

Farringdon Capital’s Neurocrine Biosciences NBIX Stock Holding History

Farringdon Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,211
Closed -$423K – 345
2026
Q1 		$423K Buy
+3,211
New +$426K 0.09% 244
2025
Q1 		– Sell
-2,318
Closed -$316K – 514
2024
Q4 		$316K Buy
+2,318
New +$287K 0.13% 264

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Farringdon Capital's NBIX Position: Q2 2026 in Review

Farringdon Capital sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 3,211 shares — an estimated $423K sold.

Farringdon Capital first reported a position in NBIX in Q4 2024 and held it in 2 quarters. The position peaked at $423K in Q1 2026. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Farringdon Capital reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • Farringdon Capital sold 3,211 Neurocrine Biosciences shares in Q2 2026, an estimated $423K.
  • Farringdon Capital first reported a position in Neurocrine Biosciences in Q4 2024 and held it in 2 quarters.
  • Farringdon Capital's Neurocrine Biosciences position peaked at $423K in Q1 2026.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Farringdon Capital's 13F filing for Q2 2026, filed 12 Aug 2026.